How it works, simply
It activates a hormone receptor involved in building bone.
What the evidence tells us
Benefits and risks apply to the labeled osteoporosis population, not to untested enhancement uses.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Dizziness, orthostatic symptoms and increased calcium are relevant concerns.
- The label advises avoiding use in people with certain increased risks of osteosarcoma.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates the PTH1 receptor to stimulate bone formation.
Sponsor or developer: Radius Health
Studied or labeled topics: Osteoporosis, High fracture risk
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: TYMLOS prescribing information ↗ · Regulator · Aug 17, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.